Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 389

1.

Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey.

Kojima M, Nakayama T, Tsutani K, Igarashi A, Kojima T, Suzuki S, Miyasaka N, Yamanaka H.

Mod Rheumatol. 2019 Nov 14:1-7. doi: 10.1080/14397595.2019.1682776. [Epub ahead of print]

PMID:
31625435
2.

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.

Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Sciré C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Lioté F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinambá HA, Yamanaka H, Choi HK, Mackay J, ODell JR, Vázquez Mellado J, Singh JA, Fitzgerald JD, Jacobsson LTH, Joosten L, Harrold LR, Stamp L, Andrés M, Gutierrez M, Kuwabara M, Dehlin M, Janssen M, Doherty M, Hershfield MS, Pillinger M, Edwards NL, Schlesinger N, Kumar N, Slot O, Ottaviani S, Richette P, MacMullan PA, Chapman PT, Lipsky PE, Robinson P, Khanna PP, Gancheva RN, Grainger R, Johnson RJ, Te Kampe R, Keenan RT, Tedeschi SK, Kim S, Choi SJ, Fields TR, Bardin T, Uhlig T, Jansen T, Merriman T, Pascart T, Neogi T, Klück V, Louthrenoo W, Dalbeth N.

Ann Rheum Dis. 2019 Nov;78(11):1592-1600. doi: 10.1136/annrheumdis-2019-215933. Epub 2019 Sep 9.

PMID:
31501138
3.

A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today's treatment options.

Yamanaka H, Tanaka E, Nakajima A, Furuya T, Ikari K, Taniguchi A, Inoue E, Harigai M.

Mod Rheumatol. 2019 Oct 1:1-6. doi: 10.1080/14397595.2019.1660028. [Epub ahead of print]

PMID:
31475852
4.

A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week).

Nanke Y, Kobashigawa T, Sugimoto N, Yamanaka H, Kotake S.

Immunol Med. 2019 Jun;42(2):99-102. doi: 10.1080/25785826.2019.1657255. Epub 2019 Aug 25.

PMID:
31446856
5.

Updated version of Japanese Childhood Health Assessment Questionnaire (CHAQ).

Miyamae T, Tani Y, Kishi T, Yamanaka H, Singh G.

Mod Rheumatol. 2019 Sep 19:1-5. doi: 10.1080/14397595.2019.1660027. [Epub ahead of print]

PMID:
31441680
6.

Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor.

Ishikawa Y, Ikari K, Hashimoto M, Ohmura K, Tanaka M, Ito H, Taniguchi A, Yamanaka H, Mimori T, Terao C.

Ann Rheum Dis. 2019 Nov;78(11):1480-1487. doi: 10.1136/annrheumdis-2019-215463. Epub 2019 Aug 19.

PMID:
31427439
7.

Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database.

Sakai R, Tanaka E, Nishina H, Suzuki M, Yamanaka H, Harigai M.

Int J Rheum Dis. 2019 Nov;22(11):1978-1984. doi: 10.1111/1756-185X.13662. Epub 2019 Jul 23.

PMID:
31338986
8.

Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.

Tanaka Y, Mimori T, Yamanaka H, Sunaga N, Morita K, Kimura J, Takeuchi T.

Mod Rheumatol. 2019 Jul 22:1-10. doi: 10.1080/14397595.2019.1639931. [Epub ahead of print]

PMID:
31267801
9.

Age and female gender associated with periodontal disease in Japanese patients with rheumatoid arthritis: Results from self-reported questionnaires from the IORRA cohort study.

Furuya T, Inoue E, Tanaka E, Maeda S, Ikari K, Taniguchi A, Yamanaka H.

Mod Rheumatol. 2019 Jun 7:1-6. doi: 10.1080/14397595.2019.1621461. [Epub ahead of print]

PMID:
31116056
10.

Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study.

Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Yokota I, Atsumi T, Takeuchi T.

Mod Rheumatol. 2019 Jun 7:1-8. doi: 10.1080/14397595.2019.1621026. [Epub ahead of print]

PMID:
31106666
11.

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.

Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D.

Ann Rheum Dis. 2019 Jul;78(7):899-907. doi: 10.1136/annrheumdis-2018-214827. Epub 2019 Apr 29.

12.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

13.

Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment.

Higuchi T, Takagi K, Tochimoto A, Ichimura Y, Norose T, Katsumata Y, Masuda I, Yamanaka H, Morohoshi T, Kawaguchi Y.

Arthritis Res Ther. 2019 Apr 18;21(1):103. doi: 10.1186/s13075-019-1881-3.

14.

Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.

Lee EB, Yamanaka H, Liu Y, Tsai WC, Chen C, Kwok K, Yoo HJ, Llamado LJ, Wang L, Luo Y, Sugiyama N, Tanaka Y.

Int J Rheum Dis. 2019 Jun;22(6):1094-1106. doi: 10.1111/1756-185X.13516. Epub 2019 Mar 22.

15.

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.

van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators.

Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24.

16.

Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.

Ishiguro N, Tanaka Y, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D, Takeuchi T.

Rheumatology (Oxford). 2019 Jun 1;58(6):997-1005. doi: 10.1093/rheumatology/key416.

17.

Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.

Takeuchi T, Yamanaka H, Yamaoka K, Arai S, Toyoizumi S, DeMasi R, Fukuma Y, Hirose T, Sugiyama N, Zwillich SH, Tanaka Y.

Mod Rheumatol. 2019 Sep;29(5):756-766. doi: 10.1080/14397595.2018.1553489. Epub 2019 Jan 11.

PMID:
30489177
18.

KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker.

Hanaoka M, Katsumata Y, Kawasumi H, Kawaguchi Y, Yamanaka H.

Mod Rheumatol. 2019 Jul;29(4):625-632. doi: 10.1080/14397595.2018.1553488. Epub 2019 Jan 8.

PMID:
30484723
19.

Neurodevelopmental disorders associated with juvenile fibromyalgia.

Miyamae T, Chiba Y, Kato I, Tani Y, Yamanaka H.

Pediatr Int. 2018 Nov;60(11):1034-1035. doi: 10.1111/ped.13696. Epub 2018 Nov 8. No abstract available.

PMID:
30407706
20.

Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity.

Sakaue S, Hirata J, Maeda Y, Kawakami E, Nii T, Kishikawa T, Ishigaki K, Terao C, Suzuki K, Akiyama M, Suita N, Masuda T, Ogawa K, Yamamoto K, Saeki Y, Matsushita M, Yoshimura M, Matsuoka H, Ikari K, Taniguchi A, Yamanaka H, Kawaji H, Lassmann T, Itoh M, Yoshitomi H, Ito H, Ohmura K, R Forrest AR, Hayashizaki Y, Carninci P, Kumanogoh A, Kamatani Y, de Hoon M, Yamamoto K, Okada Y.

Nucleic Acids Res. 2018 Dec 14;46(22):11898-11909. doi: 10.1093/nar/gky1066.

Supplemental Content

Loading ...
Support Center